바로가기메뉴

본문 바로가기 주메뉴 바로가기

ACOMS+ 및 학술지 리포지터리 설명회

  • 한국과학기술정보연구원(KISTI) 서울분원 대회의실(별관 3층)
  • 2024년 07월 03일(수) 13:30
 

logo

  • E-ISSN2671-6771

Novel variants of IDS gene, c.1224_1225insC, and recombinant variant of IDS gene, c.418+495_1006+1304del, in two families with Mucopolysaccharidosis type II

유전의학융합학술지 / Journal of Interdisciplinary Genomics, (E)2671-6771
2019, v.1 no.1, pp.6-9
https://doi.org/10.22742/JIG.2019.1.1.6
Chong Kun Cheon (Department of Pediatrics, Pediatric Genetics and Metabolism, Pusan National University Children’s Hospital, Pusan National University School of Medicine, Yangsan, Korea)

Abstract

In this report, the phenotypes of three patients from two families with mucopolysaccharidosis type II (MPS II) are compared: a novel variant and recombinant variant of IDS gene. The results of urine in patients showed a pronounced increase in glycosaminoglycan excretion with decreased iduronate-2-sulfatase enzyme activity in leukocyte, leading to a diagnosis of MPS II. A patient has a novel variant with 1 bp small insertion, c.1224_1225insC in exon 9, which caused frameshifts with a premature stop codon, and two patients have a recombination variant, c.418+495¬¬_1006+1304del, leading to the loss of exons 4, 5, 6, and 7 in genomic DNA, which is relatively common in Korean patients. They had different phenotypes even in the same mutation. The patients have now been enzyme replacement therapy with a significant decrease in glycosaminoglycan excretion. Further study on residual enzyme activity, as well as experience with more cases, may shed light on the relationship between phenotypes in MPS II and gene mutations.

keywords
Mucopolysaccharidosis type II, Iduronate-2-sulfatase, Enzyme replacement therapy
투고일Submission Date
2019-03-30
수정일Revised Date
2019-04-05
게재확정일Accepted Date
2019-04-12

유전의학융합학술지